1. Taiwan, Province of China Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Bioptik Technology Incorporation

Bioptik Technology Incorporation

4161.TWO
Bioptik Technology IncorporationTW flagTaipei Exchange
22.95
TWD
-0.10
- -
1.37BMarket Cap
Bioptik Technology Incorporation
4161.TWO
(Taipei Exchange)

Recent

price

22.95

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
5.54
6.14
6.82
8.68
7.39
7.31
7.71
7.7
8.77
9.89
8.48
12.88
13.4
14.39
14.95
- -
14.58
Revenue per Share
0.44
0.11
0.14
1.52
0.53
0.45
0.12
-0.54
0.45
0.09
-1.05
0.39
0.85
1.49
1.62
- -
1.24
Basic EPS, GAAP
-1.25
-0.31
-0.35
-0.74
-2.24
-1.73
-1.07
-0.84
-0.17
0.22
-0.12
-1.06
0.66
3.04
2.48
- -
0.65
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
0.83
0.4
0.81
- -
0.42
0.51
0.25
0.25
- -
0.64
- -
- -
Dividend per Share
7.59
7
7.13
9.01
9.94
10.19
9.86
9.02
8.22
9.25
8.15
9.57
9.26
9.23
10.79
- -
11.73
Book Value per Share
6.99
6.8
7.72
11.74
14.38
16.79
16.76
14.33
13.69
13.39
12.83
12.11
12.53
14.31
15.64
- -
16.93
Tangible Book Value per Share
44
48
48
52
56
62
62
62
59
57
57
57
57
58
58
- -
57
Basic Weighted Avg Shares
244
297
330
452
415
453
477
476
520
566
486
738
768
829
865
837
837
Sales/Revenue/Turnover
2.4
6.74
5.67
10.93
6.42
12.31
3.71
1.04
0.14
0.08
-9.01
4.8
5.11
10.89
10.4
7.95
7.95
Operating Margin (%)
11
13
17
18
22
23
27
33
33
41
38
37
33
35
36
33
33
Depreciation Expense
19
5
7
79
30
28
8
-34
26
5
-60
23
48
86
94
71
71
Net Income, GAAP
- -
- -
10.59
13.02
27.19
34.65
47.8
- -
27.66
- -
- -
- -
25.12
20.56
16.3
18.14
18.14
Effective Tax Rate (%)
7.87
1.76
2.04
17.51
7.15
6.14
1.61
-7.08
5.08
0.93
-12.35
3.06
6.32
10.35
10.81
8.5
8.5
Profit Margin (%)
213
164
234
317
466
538
454
574
452
388
269
250
253
355
417
451
451
Working Capital
46
38
75
- -
78
38
- -
325
311
311
259
219
179
155
133
112
112
LT Debt
342
364
375
613
809
1,040
1,038
887
812
768
736
695
718
824
905
975
975
Total Equity
- -
4.38
3.29
7.2
2.29
3.05
0.67
- -
0.04
- -
- -
- -
2.12
5.21
5.51
3.86
3.86
Return on Invested Capital (%)
- -
2.06
0.82
15.95
5.47
3.61
1.35
- -
3.12
- -
- -
- -
4.67
8.47
9.58
7.07
7.07
Return on Capital (%)
7.65
1.56
1.97
19.43
5.78
4.67
1.24
-5.77
5.05
1.03
-12.04
4.45
8.99
16.14
16.19
10.97
10.97
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
285
305
358
LT Borrowings
122
116
111
LT Finance Leases
2
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
60
60
60
Market Capitalization
1,720
1,645
1,433

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
805
820
936
Cash, Cash Equivalents & STI
369
362
448
Accounts Receivable, Net
45
66
38
Inventories
209
201
203
Total Current Liabilities
389
397
484
Payables & Accruals
- -
- -
- -
ST Debt
285
305
358
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.28%
6.02%
7.67%
Free Cash Flow
41.26%
185.84%
-74.05%
Net Income, GAAP
-207.2%
7.8%
-23.92%
Sales/Revenue/Turnover
7.42%
13.02%
-3.25%
Total Cash Common Dividend
- -
- -
-57.18%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
157
189
236
247
829
2024
220
208
210
228
865
2025
196
190
215
236
837

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
0.14
0.22
0.55
- -
1.49
2024
0.31
0.5
0.31
- -
1.62
2025
0.26
0.07
0.45
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
0.64
2025
- -
- -
- -
- -
- -
Similar Companies
Koninklijke Philips N.V. (RYLPF)
Euromedis Groupe (ALEMG.PA)
Vicarious Surgical Inc. WT (RBOT-WT)
ScandiDos AB (publ) (SDOS.ST)
Tactile Systems Technology, Inc. (TCMD)
Viemed Healthcare, Inc. (VMD)
Business
Bioptik Technology Incorporation Bioptik Technology Incorporation engages in the research, development, manufacturing, wholesale, and retail of biotechnology and medical equipment, including multi-functional diagnostic devices, health supplements, skincare products, and pet healthcare solutions, primarily in Taiwan and internationally. The company offers EasyMate blood glucose monitoring systems; blood glucose, cholesterol, uric acid, and hemoglobin monitoring systems and corresponding test strips; hyaluronic acid-based skincare products; dietary supplements in forms such as powders, tablets, capsules, beverages, and jellies featuring ingredients like astaxanthin; beauty care lines focused on whitening, radiance, firming, and anti-aging; and pet blood glucose monitors with rapid test kits for blood sugar, infectious diseases, and other health indicators. Bioptik Technology Incorporation, founded in 1999 and headquartered at No. 188, Jhonghua South Road, Zhunan Township, Miaoli County, Taiwan, operates production facilities in Zhunan for medical devices and reagents, Hsinchu for skincare, and Tainan for bioenergy developments including biodiesel, astaxanthin, and cellulose bioethanol; it maintains three R&D departments supporting OEM and ODM services for medical testing, dietary supplements, and cosmetics. The company, a publicly listed entity on the Taipei Exchange under ticker 4161, continues to expand its global sales of core monitoring systems and strips while emphasizing innovations in home health management for chronic conditions like high blood pressure, cholesterol, and blood sugar, alongside diversified offerings in beauty and pet care without notable recent acquisitions, partnerships, or major strategic shifts reported in the past one to two years.